MMP9 and neoplasm: Zymogel quantification showed that BSG invalidation does not significantly affect MMP2 and MMP9 production by LS174T (Figure 1C lanes d, e, Figure 2A lanes a, b, and Figure 2B–2C), U87 (Figure 1C lanes h, i, Figure 3A lanes a, b, c and Figure 3B–3C), and A549 (Figure 1C lanes f, g) tumour cells.